Systematic Review and Network Meta-Analysis of Initial Treatments for Lupus Nephritis
In a systematic review and network meta-analysis of 40 RCTs, adding voclosporin, belimumab, or obinutuzumab to mycophenolic acid analogs significantly increased complete renal response over mycophenolic acid analogs alone for the initial treatment of lupus nephritis.
Background
Lupus nephritis is a major complication of systemic lupus erythematosus, and complete renal response remains difficult to achieve with standard immunosuppression. Multiple newer combination regimens have entered practice, but their comparative efficacy and safety for initial therapy had not been comprehensively ranked.
Study design
The authors searched multiple databases through 2025 for randomized controlled trials comparing initial treatments for active lupus nephritis and performed a frequentist random-effects network meta-analysis, assessing certainty of evidence with the GRADE approach. The final analysis included 40 RCTs encompassing 5,450 patients and 16 interventions (12 drugs alone or in combination), with mycophenolic acid analogs (MPAA) as the common comparator.
Key findings
Compared with MPAA alone, complete renal response increased with voclosporin plus MPAA (risk difference 281 more per 1,000, 95% CI 146 to 456; high certainty), belimumab plus MPAA (145 more per 1,000, 95% CI 73 to 231; high certainty), and obinutuzumab plus MPAA (134 more per 1,000, 95% CI 30 to 270; moderate certainty). Tacrolimus plus MPAA also showed a potential benefit (114 more per 1,000, 95% CI 25 to 218) but with low-certainty evidence. Effects on mortality and need for kidney replacement therapy remained highly uncertain.
Clinical implications
Combination therapies, particularly voclosporin or belimumab added to a mycophenolic acid analog, may provide enhanced renal outcomes for initial lupus nephritis treatment. Because evidence for hard endpoints such as mortality and kidney replacement therapy is limited, clinicians should weigh these findings alongside drug availability, cost, and individual patient preferences.
Category
Research
Source
Kidney International Reports
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.